Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Hawkins has announced that it recently completed its acquisition of Stauber Performance Ingredients from ICV Partners II, L.P. and its other shareholders in a cash for stock transaction.
read more
NeoGenomics, a provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc. Clarient, a provider of comprehensive ...
read more
Cepheid has announced an agreement with Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc., for the distribution of its GeneXpert® System and menu of 17 Xpert® tests spanning healthcare associated infections, critical infectious ...
read more
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, has announced that Paul Korner, MD, MBA, joined the Company in a newly created position as Executive Vice President and Chief Medical ...
read more
Tuesday, December 29, 2015
Epizyme, Inc., has announced that the U.S. Food and Drug Administration’s (FDA) Division of Hematology Products has accepted the company’s investigational new drug (IND) application for tazemetostat for the treatment of adults with diffuse large B-...
read more
Tuesday, December 29, 2015
Ash Stevens’ Riverview manufacturing facility is pleased to announce it has been recognized for exemplary efforts in improving its environmental, health, safety and security (EHS&S) operations by the Society of Chemical Manufacturers and Affiliates (...
read more
Tuesday, December 29, 2015
PixarBio Corporation announced today the appointment of Steven Chartier as V.P. of Regulatory Affairs.
read more
Tuesday, December 29, 2015
Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced that it has acquired all of the remaining rights, title and interest in and ...
read more
Tuesday, December 29, 2015
Roughly half of all surveyed global and U.S. pharmaceutical teams report involving key opinion leader (KOL) management or medical science liaison (MSL) teams in their investigator-initiated trial (IIT) proposal collection processes.
read more
Tuesday, December 29, 2015
Mylan has announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox® Tablets.
read more
Tuesday, December 29, 2015
CMC Biologics, Inc. today announced that they have entered into an agreement with Immunocore Limited, a leading UK-based biotechnology company focused on developing new treatments for cancer, viral infections and autoimmune diseases, for the process ...
read more
Tuesday, December 29, 2015
Biotechnology companies continue to forge ahead with advancing clinical trials and development of next-generation treatments for rare diseases through new orphan drug designations and cutting edge drug delivery products.
read more
Tuesday, December 29, 2015
Pfizer Inc. today announced that it has completed its acquisition of Hospira, Inc.
read more
Monday, December 28, 2015
Agenus Inc., an immunotherapy company developing innovative treatments for cancer, today announced that it has acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens.
read more
Monday, December 28, 2015
Seattle Genetics, Inc. and Bristol-Myers Squibb have announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with CD30-expressing relapsed or ...
read more